We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




Greiner Bio-One to Serve Spain and Portugal through Distribution Subsidiaries

By LabMedica International staff writers
Posted on 28 Mar 2017
Greiner Bio-One has acquired its long-standing distribution partners, VacuetteEspaña and Vacuette Portugal, which will now allow the medical technology company to serve its customers in Spain and Portugal directly through its own distribution subsidiaries.

Greiner Bio-One, a part of the Greiner Group, specializes in the development, production and distribution of high-quality plastic products for laboratory use. More...
The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry and biotechnology.

For over 20 years, the Greiner Group has worked with VacuetteEspaña, S.A. and Vacuette Portugal Importação e Exportação de Material Hospitalar, S.A., both of which were previously exclusive distributors for Greiner Bio-One International on the Iberian Peninsula. Towards the end of February 2017, Greiner Bio-One entered into official acquisition agreements with both of its distribution partners that came into effect on March 1, 2017. The two subsidiaries in Madrid and Porto will now continue to supply directly to their customers in both the markets.

“Having our own local subsidiaries will bring us closer to our customers and enable us to cater to our markets even more effectively at an international level. The acquisition of VacuetteEspaña and Vacuette Portugal is another key step in our globalization strategy,” said Axel Kühner, Chairman of the Management Board of the Greiner Group.

“Following the establishment of our own distribution subsidiaries in Turkey and Italy last year, the new Greiner Bio-One sites in Spain and Portugal are the next step in systematic implementation of our distribution strategy in Europe,” added Rainer Perneker, CEO of Greiner Bio-One International.

“By attaining greater proximity to customers, we aim to develop the two markets on the Iberian Peninsula in an even more targeted way. The acquisitions mark the continuation of our growth over many years and allow us to step up services and customer care at the local level,” said Manfred Buchberger, CEO of Greiner Bio-One Preanalytics.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.